Castle Biosciences on Tuesday announced the presentation of a case study showcasing the performance of DiffDx-Melanoma, its diagnostic gene expression profile (GEP) test. The study was presented in poster form at the College of American Pathologists 2022 (CAP22) Annual Meeting in New Orleans.
DiffDx-Melanoma is designed to help diagnose ambiguous melanocytic lesions, Castle said.
In the case study presented at CAP22, the test supported the need to perform local excision on a difficult-to-diagnose melanocytic lesion after dermoscopy, reflectance confocal microscopy, and/or histopathological assessment did not achieve clinicopathological correlation, the company also said.
“Castle’s DiffDx-Melanoma test is a highly accurate ancillary test that can provide additional diagnostic information, as shown through the case study presented, that can help clinicians determine the appropriate next steps in a patient’s overall care,” Dr. Harold Rabinovitz, professor of dermatology at the Medical College of Georgia and the poster’s presenter, said in a statement.